Fishawack Health announces the appointment of Jonathan (Jon) Koch as its new CEO.
Jon’s appointment follows the announcement of Liz Landon as Chief People Officer.
Jon has a significant track record in transforming businesses and managing large, global, customer-centered organizations. He has spent his entire career in the healthcare sector, including nearly 12 years at Covance (now Labcorp Drug Development), serving last as Group President of Clinical Development and Commercialization services, leading more than 11,000 employees across dozens of countries. Most recently, Jon served as Senior Vice President and CEO of Global Dental at the publicly listed organization Henry Schein, where he was responsible for the strategic direction and business performance of its largest healthcare division and leading technology business.
Jon subscribes to a people-led philosophy and believes in the power of diverse teams. “I’m incredibly excited to join Fishawack Health,” says Jon. “The organization delivers exceptional work across the product and service lifecycle and has an enviable roster of life science and medical device clients, as well as healthcare startups. I look forward to contributing my knowledge of building dynamic businesses that generate exceptional results for customers, their stakeholders, and our team members.”
The Misinformation Maze: Navigating Public Health in the Digital Age
March 11th 2025Jennifer Butler, chief commercial officer of Pleio, discusses misinformation's threat to public health, where patients are turning for trustworthy health information, the industry's pivot to peer-to-patient strategies to educate patients, and more.
Navigating Distrust: Pharma in the Age of Social Media
February 18th 2025Ian Baer, Founder and CEO of Sooth, discusses how the growing distrust in social media will impact industry marketing strategies and the relationships between pharmaceutical companies and the patients they aim to serve. He also explains dark social, how to combat misinformation, closing the trust gap, and more.